newsdesk@dailyround.news 
Industry Insight
The UK’s fastest-growing news and insight platform for the care sector.
In-depth articles exploring the trends, challenges, innovations and opportunities shaping the care sector—helping you stay informed and make smarter decisions.
The UK has become the first country in Europe to approve an oral version of Wegovy (semaglutide), marking a significant milestone in the treatment of obesity and weight-related health conditions.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide tablets for weight management in adults living with obesity or those who are overweight with weight-related health conditions.
The announcement follows growing demand for GLP-1 medicines such as Wegovy and Mounjaro, which have transformed the conversation around obesity treatment over the past three years.
However, while the approval has generated considerable interest, questions remain around NHS access, private prescribing and what the introduction of a tablet version could mean for patients and healthcare services.
Until now, Wegovy has been available as a once-weekly injection.
The newly approved tablet contains the same active ingredient, semaglutide, but is taken orally once a day.
For many patients, the prospect of a tablet rather than an injection may make treatment more accessible and acceptable, particularly for those who are uncomfortable with self-injection.
Healthcare experts believe the introduction of an oral option could significantly increase demand for treatment in the coming years.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists.
The medication works by mimicking a naturally occurring hormone that helps regulate appetite and food intake, allowing patients to feel fuller for longer and reduce calorie consumption.
Clinical trials have demonstrated significant weight-loss benefits.
The OASIS 1 trial, published in The Lancet, found that participants taking oral semaglutide achieved an average weight reduction of 15.1% of their body weight over 68 weeks when combined with lifestyle interventions, compared with 2.4% in the placebo group.
Researchers reported that more than three-quarters of participants achieved at least 5% weight loss, while many achieved substantially greater reductions.
These results are comparable to those previously seen with injectable semaglutide and have helped drive global interest in oral treatment options.
The approval applies to adults with:
Patients must also use the medication alongside dietary changes and increased physical activity.
Although the medicine has now been approved by the MHRA, approval does not automatically mean immediate NHS availability.
The National Institute for Health and Care Excellence (NICE) will still need to review the treatment before determining whether it should be routinely funded within NHS weight-management services.
In the meantime, it is expected that access will primarily be through private healthcare providers.
This means there may initially be a significant difference between patients who can access treatment privately and those waiting for NHS eligibility pathways to develop.
While public discussion often focuses on appearance and weight reduction, obesity remains one of the UK’s most significant public health challenges.
According to NHS England, obesity is associated with an increased risk of:
Healthcare leaders increasingly view obesity as a chronic medical condition requiring long-term management rather than simply a lifestyle issue.
The introduction of additional treatment options may therefore have implications far beyond weight management alone.
The growing use of medications such as Wegovy and Mounjaro means awareness is no longer limited to obesity specialists.
Healthcare professionals working across primary care, hospitals, social care, mental health services, community services and care homes are increasingly likely to encounter patients using GLP-1 treatments.
These medicines may influence:
Understanding how these medicines work, their benefits and their potential side effects will become increasingly important as more patients begin treatment.
For healthcare providers, this represents a significant shift in the way obesity is understood and managed across the health and care system.
The approval of oral Wegovy represents another major development in a rapidly evolving area of healthcare.
Whether it ultimately improves access for patients remains to be seen, but healthcare leaders agree on one thing: demand for effective obesity treatment is unlikely to slow down.
As NHS and private providers continue to adapt, the arrival of a tablet-based option could make treatment more accessible for many people living with obesity and related health conditions.
Posted by:
Mehala
Editorial Assistant – The Daily Round
Sign up to receive daily insights, sector news, and opportunities. Tell us a little about yourself below so we can personalise what you receive.
Sign up to receive daily insights, sector news, and opportunities. Tell us a little about yourself below so we can personalise what you receive.